Reaction

Lacunar Infarction reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,362 reports · 62 co-occurring drugs

As of the last recalculation, Lacunar Infarction appears in 2,362 FAERS reports alongside 62 co-occurring drug terms. The strongest observed disproportionality signal is PRASUGREL HYDROCHLORIDE (PRR 18.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Prasugrel Hydrochloride	21	18.4	18.4
Amlodipine Besylate And Benazepril Hydrochloride	15	14.4	14.4
Enalapril Maleate	38	13.7	13.7
Dalteparin Sodium	15	12.6	12.6
Glyburide	28	10.3	10.3
Febuxostat Tablets 40 Mg	11	9.6	9.6
Febuxostat Tablets 80 Mg	11	9.6	9.6
Pitavastatin Calcium	11	9.5	9.5
Nifedipine	47	8.9	8.9
Amiodarone Hydrochloride	11	8.7	8.7
Testosterone	22	8.4	8.4
Basiliximab	11	8.3	8.3
Cimetidine	9	8.3	8.3
Bicalutamide	14	8.1	8.1
Meclizine Hcl 12.5Mg	12	7.8	7.8
Meclizine Hcl 25Mg	12	7.8	7.8
Meclizine Hcl 12.5 Mg	12	7.8	7.8
Meclizine Hcl 25 Mg	12	7.8	7.8
Losartan Potassium And Hydrochlorothiazide	10	7.6	7.6
Donepezil Hydrochloride	31	7.5	7.5
Rabeprazole Sodium	23	7.5	7.5
Atropine	7	7.5	7.5
Conjugated Estrogens	48	7.4	7.4
Atropine Sulfate	9	7.4	7.4
Estrogens, Conjugated	48	7.3	7.3
Salmeterol Xinafoate	7	7.2	7.2
Testosterone Cypionate	7	6.9	6.9
Febuxostat	13	6.9	6.9
Epoetin Alfa	9	6.7	6.7
Raloxifene Hydrochloride	11	6.7	6.7
Amlodipine Besylate	106	6.6	6.6
Valsartan	76	6.6	6.6
Micafungin Sodium	6	6.2	6.3
Niacin	8	6.1	6.1
Enalapril	37	5.9	5.9
Gefitinib	6	5.9	5.9
Clopidogrel	126	5.9	5.9
Romosozumab-Aqqg	9	5.9	5.9
Cefepime	9	5.5	5.6
Insulin Glargine-Yfgn	13	5.3	5.3
Memantine	8	5.2	5.2
Memantine Hydrochloride	8	5.2	5.2
Miconazole Nitrate	5	5.1	5.1
Ranibizumab	15	5.0	5.0
Cefepime Hydrochloride	9	4.9	4.9
Pioglitazone	24	4.9	4.9
Rivastigmine	9	4.2	4.2
Crizotinib	6	4.2	4.2
Methoxy Polyethylene Glycol-Epoetin Beta	5	4.0	4.0
Insulin Degludec	10	3.8	3.8
Darbepoetin Alfa	22	3.6	3.6
Drospirenone And Ethinyl Estradiol	18	3.6	3.6
Dabigatran Etexilate Mesylate	28	3.4	3.4
Conjugated Estrogens And Medroxyprogesterone Acetate	9	3.4	3.4
Loratadine And Pseudoephedrine Sulfate	3	3.3	3.3
Dabigatran Etexilate	28	3.2	3.2
Emicizumab	4	2.9	2.9
Suvorexant	4	2.7	2.7
Polatuzumab Vedotin	3	2.7	2.7
Atezolizumab	11	2.5	2.5
Aflibercept	7	2.0	2.0
Galcanezumab-Gnlm	4	1.1	1.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.